Robert Raymond Lavieri
Affiliations: | 2014 | Pharmacology | Vanderbilt University, Nashville, TN |
Google:
"Robert Lavieri"Mean distance: 8.55 | S | N | B | C | P |
Parents
Sign in to add mentor| Craig W. Lindsley | grad student | 2014 | Vanderbilt | |
| (Synthesis, development and biochemical characterization of small molecule, isoform-selective phospholipase D inhibitors and photoactivatable probes.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Challa AP, Beam AL, Shen M, et al. (2020) Machine learning on drug-specific data to predict small molecule teratogenicity. Reproductive Toxicology (Elmsford, N.Y.) |
| Pulley JM, Shirey-Rice JK, Lavieri RR, et al. (2017) Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay and Drug Development Technologies |
| Scott SA, Spencer CT, O'Reilly MC, et al. (2015) Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes. Acs Chemical Biology. 10: 421-32 |
| Selvy PE, Lavieri RR, Lindsley CW, et al. (2011) Phospholipase D: enzymology, functionality, and chemical modulation. Chemical Reviews. 111: 6064-119 |
| Lavieri RR, Scott SA, Selvy PE, et al. (2010) Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. Journal of Medicinal Chemistry. 53: 6706-19 |
| Lavieri R, Scott SA, Lewis JA, et al. (2009) Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorganic & Medicinal Chemistry Letters. 19: 2240-3 |
| Lewis JA, Scott SA, Lavieri R, et al. (2009) Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorganic & Medicinal Chemistry Letters. 19: 1916-20 |